Last reviewed · How we verify
Comirnaty Injectable Product
At a glance
| Generic name | Comirnaty Injectable Product |
|---|---|
| Also known as | Comirnaty 3µg/dose for children for 6 month - 4 years |
| Sponsor | Technical University of Munich |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (PHASE1, PHASE2)
- A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection (PHASE2)
- Anti-viral Action Against Type 1 Diabetes Autoimmunity (PHASE4)
- Drug Use Investigation of COMIRNATY Intramuscular Injection
- Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. (PHASE2)
- National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE) (PHASE4)
- Immunocompromised Swiss Cohorts Based Trial Platform (PHASE3)
- Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comirnaty Injectable Product CI brief — competitive landscape report
- Comirnaty Injectable Product updates RSS · CI watch RSS
- Technical University of Munich portfolio CI